Childhood Central Nervous System Germ Cell Tumor
16
0
0
16
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (16)
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Sunitinib in Treating Young Patients With Refractory Solid Tumors
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Irinotecan in Treating Children With Refractory Solid Tumors
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia